Doerthe Eckert

Pharmacokinetics and Exposure–Efficacy Relationship of Adalimumab in Pediatric Patients with Moderate to Severe Crohnʼs Disease

Shringi Sharma, Doerthe Eckert, Jeffrey S. Hyams et al. · Inflammatory Bowel Diseases · 2015 · 97 citations · Full text

Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

Kevin J. Freise, Aksana K. Jones, Doerthe Eckert et al. · Clinical Pharmacokinetics · 2016 · 61 citations

Hematological Malignancy, Lymphoid Neoplasia, Medicine +7

Venetoclax exposure‐efficacy and exposure‐safety relationships in patients with treatment‐naïve acute myeloid leukemia who are ineligible for intensive chemotherapy

Deanna J. Brackman, Doerthe Eckert, Rajeev Menon et al. · Hematological Oncology · 2022 · 44 citations · Full text

Mixed-phenotype Acute Leukemia, Pharmacotherapy, Myeloid Neoplasia +16

Pharmacokinetics of Risankizumab in Asian Healthy Subjects and Patients With Moderate to Severe Plaque Psoriasis, Generalized Pustular Psoriasis, and Erythrodermic Psoriasis

Amit Khatri, Doerthe Eckert, Rajneet K. Oberoi et al. · The Journal of Clinical Pharmacology · 2019 · 29 citations · Full text

White Healthy Subjects, Translational Medicine, Autoimmune Disease +13

Upadacitinib Population Pharmacokinetics and Exposure-Response Relationships in Ulcerative Colitis Patients

Ana Victoria Ponce Bobadilla, Sven Stodtmann, Doerthe Eckert et al. · Clinical Pharmacokinetics · 2022 · 16 citations · Full text